Literature DB >> 21356478

Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.

Søren M Bentzen1, Vincent Gregoire.   

Abstract

Dose painting is the prescription of a nonuniform radiation dose distribution to the target volume based on functional or molecular images shown to indicate the local risk of relapse. Two prototypical strategies for implementing this novel paradigm in radiation oncology are reviewed: subvolume boosting and dose painting by numbers. Subvolume boosting involves the selection of a "target within the target," defined by image segmentation on the basis of the quantitative information in the image or morphologically, and this is related to image-based target volume selection and delineation. Dose painting by numbers is a voxel-level prescription of dose based on a mathematical transformation of the image intensity of individual pixels. The quantitative use of images to decide both where and how to delivery radiation therapy in an individual case is also called theragnostic imaging. Dose painting targets are imaging surrogates for cellular or microenvironmental phenotypes associated with poor radioresponsiveness. In this review, the focus is on the following positron emission tomography tracers: FDG and choline as surrogates for tumor burden, fluorothymidine as a surrogate for proliferation (or cellular growth fraction) and hypoxia-sensitive tracers, including [(18)F] fluoromisonidazole, EF3, EF5, and (64)Cu-labeled copper(II) diacetyl-di(N(4)-methylthiosemicarbazone) as surrogates of cellular hypoxia. Research advances supporting the clinicobiological rationale for dose painting are reviewed as are studies of the technical feasibility of optimizing and delivering realistic dose painted radiation therapy plans. Challenges and research priorities in this exciting research field are defined and a possible design for a randomized clinical trial of dose painting is presented.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21356478      PMCID: PMC3052283          DOI: 10.1016/j.semradonc.2010.10.001

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  96 in total

Review 1.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality.

Authors:  C C Ling; J Humm; S Larson; H Amols; Z Fuks; S Leibel; J A Koutcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

Review 2.  Hypoxia--a key regulatory factor in tumour growth.

Authors:  Adrian L Harris
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

3.  Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.

Authors:  Benjamin Movsas; J Donald Chapman; Alexandra L Hanlon; Eric M Horwitz; Richard E Greenberg; Corinne Stobbe; Gerald E Hanks; Alan Pollack
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

4.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.

Authors:  Reinhard Bos; Jacobus J M van Der Hoeven; Elsken van Der Wall; Petra van Der Groep; Paul J van Diest; Emile F I Comans; Urvi Joshi; Gregg L Semenza; Otto S Hoekstra; Adriaan A Lammertsma; Carla F M Molthoff
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

5.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.

Authors:  Hubert Vesselle; John Grierson; Mark Muzi; Jeffrey M Pugsley; Rodney A Schmidt; Peter Rabinowitz; Lanell M Peterson; Eric Vallières; Douglas E Wood
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

6.  Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation.

Authors:  Richard A Popple; Roger Ove; Sui Shen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

7.  [76Br]Bromodeoxyuridine PET in tumor-bearing animals.

Authors:  O Gardelle; U Roelcke; P Vontobel; N E Crompton; I Guenther; P Bläuenstein; A P Schubiger; H Blattmann; J E Ryser; K L Leenders; B Kaser-Hotz
Journal:  Nucl Med Biol       Date:  2001-01       Impact factor: 2.408

8.  Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus.

Authors:  G Ikeda; S Isaji; B Chandra; M Watanabe; Y Kawarada
Journal:  Cancer       Date:  1999-10-15       Impact factor: 6.860

9.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

Authors:  Roy Vergis; Catherine M Corbishley; Andrew R Norman; Jaclyn Bartlett; Sameer Jhavar; Michael Borre; Sara Heeboll; Alan Horwich; Robert Huddart; Vincent Khoo; Ros Eeles; Colin Cooper; Matthew Sydes; David Dearnaley; Chris Parker
Journal:  Lancet Oncol       Date:  2008-03-17       Impact factor: 41.316

10.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.

Authors:  Janet S Rasey; John R Grierson; Linda W Wiens; Pamella D Kolb; Jeffrey L Schwartz
Journal:  J Nucl Med       Date:  2002-09       Impact factor: 10.057

View more
  77 in total

1.  Dentofacial parameters explaining variability in retroclination of the maxillary central incisors.

Authors:  Bernd G Lapatki; Andreas Klatt; Jürgen Schulte-Mönting; Irmtrud E Jonas
Journal:  J Orofac Orthop       Date:  2007-03       Impact factor: 1.938

2.  Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma.

Authors:  A K Due; I R Vogelius; M C Aznar; S M Bentzen; A K Berthelsen; S S Korreman; C A Kristensen; L Specht
Journal:  Strahlenther Onkol       Date:  2012-05-13       Impact factor: 3.621

3.  A mass-conserving 4D XCAT phantom for dose calculation and accumulation.

Authors:  Christopher L Williams; Pankaj Mishra; Joao Seco; Sara St James; Raymond H Mak; Ross I Berbeco; John H Lewis
Journal:  Med Phys       Date:  2013-07       Impact factor: 4.071

4.  Dosimetry study of 18F-FMISO + PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer.

Authors:  H Li; D Xu; X Han; Q Ruan; X Zhang; Y Mi; M Dong; S Guo; Y Lin; B Wang; G Li
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

5.  Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.

Authors:  B Henriques de Figueiredo; T Merlin; H de Clermont-Gallerande; M Hatt; D Vimont; P Fernandez; F Lamare
Journal:  Strahlenther Onkol       Date:  2013-11-01       Impact factor: 3.621

Review 6.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

7.  Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients.

Authors:  Lotte Nygård; Marianne C Aznar; Barbara M Fischer; Gitte F Persson; Charlotte B Christensen; Flemming L Andersen; Mirjana Josipovic; Seppo W Langer; Andreas Kjær; Ivan R Vogelius; Søren M Bentzen
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

8.  A segmentation framework towards automatic generation of boost subvolumes for FDG-PET tumors: a digital phantom study.

Authors:  Fei Yang; Perry W Grigsby
Journal:  Eur J Radiol       Date:  2012-07-27       Impact factor: 3.528

9.  Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Antoi P W Meeuwis; Charlotte S van der Vos; Martin Gotthardt; Wim J G Oyen; Eric P Visser
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

10.  A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.

Authors:  Stéphanie Servagi-Vernat; Sarah Differding; Francois-Xavier Hanin; Daniel Labar; Anne Bol; John A Lee; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.